News > May > 2016

16th May 2016

PCI congratulates Vertex and Mannkind for Compliance Package of the Year Awards

Healthcare Compliance Packaging Council (HCPC) Announces Compliance Packages of the Year HCPC 2015 Compliance Package of the Year: Vertex ORKAMBI® Medication Package HCPC 2015 Compliance Package of the Year Second Runner-Up: MannKind Afrezza® Medication Package PCI is proud to congratulate Vertex and MannKind for their recent awards in the Healthcare Compliance Packaging Council’s 2015 Compliance…

16th May 2016

Frontier Medical Group scoops top honour at BVCA Management Team Awards

Frontier Medical Group, the specialist medical device manufacturer, has been named Wales Mid-Market Team of the Year at the prestigious British Private Equity & Venture Capital Association (BVCA) Management Team Awards 2016. The Awards, which are held in association with Grant Thornton UK LLP, seek to reward the best in UK business backed by private…

13th May 2016

Texas hosts first ever UK Health and life sciences delegation

Texas is about to play host to the first ever delegation of innovative medical technology companies from the United Kingdom. It is recognised that the UK has a world-leading reputation in life sciences. Its £18bn ($26.3) medical technology sector employs over 88,000 people and has changed millions of lives across the globe. This month, the…

10th May 2016

Expert advice from Geldards LLP: The general data protection regulation – how will businesses in the life sciences sector be affected?

The countdown to the General Data Protection Regulation 2016 (“GDPR”) has finally begun! It has now been published in the EU Official Journal and will automatically apply in all member states (without the need for national implementing legislation) from 25th May 2018. It will repeal the Data Protection Directive 1995 (“DPD”) and the national data…

10th May 2016

OncoTherics is raising investment to pursue a Phase II trial in pancreatic cancer

OncoTherics is raising investment to pursue a Phase II trial in pancreatic cancer with its new and exciting prodrug therapies. The company has entered the VOOM 2016 competition and need your votes – click here to add your support. The goal for OncoTherics is to develop new drugs that target areas of the tumour that conventional…

10th May 2016

Update from The Collaboration Project

Are you leading a cross-functional or cross-organisational group – such as a project team, or a tie-up between one company and another, or with academia or government bodies? The Collaboration Project is for you! It’s a free network that you can join, started earlier this year, that’s gradually building into a useful resource to help…

09th May 2016

Quay Pharma is awarded Eurostars funding for oncology project

Pharmaceutical outsourcing specialist Quay Pharma is working on a new therapy for solid tumours, for example breast cancer, as part of the EU-funded Eurostars scheme. Eurostars supports international innovative projects led by SME (small and medium-sized enterprises) research and development companies throughout Europe. It brings together organisations with varying expertise from different countries to combine…

09th May 2016

MHRA approval of Quay Pharma’s GMP manufacturing suites

Pharmaceutical outsourcing specialist Quay Pharma has received full MHRA approval for its newly-installed GMP manufacturing suites at its headquarters in Deeside. The new suites are part of a £3 million investment which has increased the company’s overall manufacturing capacity and enabled it to make larger batches of product in order to continue support through Phase…

04th May 2016

Moleculomics identifies novel host-pathogen interaction drug targets

Moleculomics, a company who specialises in high-throughput prediction of molecular interactions using cutting-edge in silico modelling and screening tools, has recently completed a project funded by the Defence Science and Technology Laboratory’s (Dstl) Centre for Defence Enterprise (CDE). It focuses on the identification of host-pathogen interactions which can be manipulated in order to devise novel…

04th May 2016

Triteq contributes to space age technology which could revolutionise cosmetic and aesthetic surgery

A newly developed plasma pen could revolutionise cosmetic and aesthetic surgery. Designed by product design consultancy Triteq Ltd for early stage company Fourth State Medicine Ltd, the pen will transform surgical procedures into non-invasive treatments, to be launched mid-2017. First used by NASA, gas plasma sterilisation isn’t new to the healthcare sector. However, the plasma pen…